Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Front-line immunosuppressive treatment of acquired aplastic anemia

    ... 60 and 80%. CsA should be given for 12 months until transfusion independence is achieved and then tapered very slowly in the ... are usually continued on CsA. Tight monitoring of the blood count during CsA tapering is necessary to identify early loss of ...

    Research Article last updated 01/02/2013 - 2:48pm.

  2. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were higher in the ...

    Research Article last updated 07/29/2014 - 12:12pm.

  3. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... of hematopoiesis that results in peripheral blood cytopenias and a marked propensity to progress to acute myelogenous ... Although supportive or palliative measures such as blood transfusion have long been the mainstay of management of MDS, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... to this approach. Patients may require frequent blood and platelet transfusion support which is expensive and inconvenient. Life-threatening ... agents can provide a new therapeutic option for enhancing blood production. In this review, we discuss these recent results and ongoing ...

    Research Article last updated 06/20/2013 - 10:13am.

  5. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes

    ... anemia . Many patients with MDS are dependent on regular blood transfusions. The study aimed to investigate symptoms of anemia and ... in patients with MDS immediately before and after blood transfusion and to capture patients' descriptions of their symptoms. ...

    Research Article last updated 01/20/2015 - 1:01pm.

  6. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... of hematopoietic stem cells and progeny mature blood cells which are deficient in some surface proteins, including the two ... clinical benefit. Anti-complement treatment allowed transfusion independence in at least half of PNH patients receiving ...

    Research Article last updated 05/22/2014 - 8:24am.

  7. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

    ... placement (ORadj=6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (ORadj=4.60, 95% CI: 2.29, 9.23) were associated with deep vein ...

    Research Article last updated 12/05/2011 - 10:09am.

  8. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... Lenalidomide (LEN) has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower risk myelodysplastic ...

    Research Article last updated 04/24/2012 - 2:47pm.

  9. Therapy for aplastic anemia

    ... in the unrelated donor registry, including cord blood. He is red cell- and platelet transfusion -dependent. He has been recommended therapy with ...

    Research Article last updated 01/09/2012 - 10:58am.

  10. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... more and longer haematological responses and increased red blood cell transfusion independence . Azacitidine prolonged overall survival versus ...

    Research Article last updated 10/11/2011 - 5:58pm.